Furthermore, we used scRNA-seq to characterize the landscape of XCL2 in different cancer cell subsets and found that XCL2 was highly enriched in immune cells, especially CD8+ T cells, NK cells, and macrophages. The gene discussed is CD8A; the disease is cancer.